Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma

• Published in: Journal of neuro-oncology 2015-03, Vol.122 (1), p.135-143
• Main Authors: Ney, Douglas E., Carlson, Julie A., Damek, Denise M., Gaspar, Laurie E., Kavanagh, Brian D., Kleinschmidt-DeMasters, B. K., Waziri, Allen E., Lillehei, Kevin O., Reddy, Krishna, Chen, Changhu
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Brain Neoplasms - diagnosis; Brain Neoplasms - mortality; Brain Neoplasms - therapy; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Study; Dacarbazine - administration & dosage; Dacarbazine - analogs & derivatives; Dose Fractionation; Female; Follow-Up Studies; Glioblastoma - diagnosis; Glioblastoma - mortality; Glioblastoma - therapy; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Neurology; Oncology; Prognosis; Prospective Studies; Radiotherapy, Intensity-Modulated - methods; Survival Rate
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-014-1691-z

Bevacizumab blocks the effects of VEGF and may allow for more aggressive radiotherapy schedules. We evaluated the efficacy and toxicity of hypofractionated intensity-modulated radiation therapy with concurrent and adjuvant temozolomide and bevacizumab in patients with newly diagnosed glioblastoma. Patients with newly diagnosed glioblastoma were treated with hypofractionated intensity modulated radiation therapy to the surgical cavity and residual tumor with a 1 cm margin (PTV1) to 60 Gy and to the T2 abnormality with a 1 cm margin (PTV2) to 30 Gy in 10 daily fractions over 2 weeks. Concurrent temozolomide (75 mg/m 2 daily) and bevacizumab (10 mg/kg) was administered followed by adjuvant temozolomide (200 mg/m 2 ) on a standard 5/28 day cycle and bevacizumab (10 mg/kg) every 2 weeks for 6 months. Thirty newly diagnosed patients were treated on study. Median PTV1 volume was 131.1 cm 3 and the median PTV2 volume was 342.6 cm 3 . Six-month progression-free survival (PFS) was 90 %, with median follow-up of 15.9 months. The median PFS was 14.3 months, with a median overall survival (OS) of 16.3 months. Grade 4 hematologic toxicity included neutropenia (10 %) and thrombocytopenia (17 %). Grades 3/4 non-hematologic toxicity included fatigue (13 %), wound dehiscence (7 %) and stroke, pulmonary embolism and nausea each in 1 patient. Presumed radiation necrosis with clinical decline was seen in 50 % of patients, two with autopsy documentation. The study was closed early to accrual due to this finding. This study demonstrated 90 % 6-month PFS and OS comparable to historic data in patients receiving standard treatment. Bevacizumab did not prevent radiation necrosis associated with this hypofractionated radiation regimen and large PTV volumes may have contributed to high rates of presumed radiation necrosis.